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Abstract
Dermatan sulfate (DS), also known as chondroitin sulfate (CS)-B, is a member of the linear
polysaccharides called glycosaminoglycans (GAGs). The expression of CS/DS and DS
proteoglycans is increased in several fibrotic renal diseases, including interstitial fibrosis, dia-
betic nephropathy, mesangial sclerosis and nephrosclerosis. Little, however, is known about
structural alterations in DS in renal diseases. The aim of this study was to evaluate the renal
expression of two different DS domains in renal transplant rejection and glomerular patholo-
gies. DS expression was evaluated in normal renal tissue and in kidney biopsies obtained
from patients with acute interstitial or vascular renal allograft rejection, patients with interstitial
fibrosis and tubular atrophy (IF/TA), and from patients with focal segmental glomerulosclero-
sis (FSGS), membranous glomerulopathy (MGP) or systemic lupus erythematosus (SLE),
using our unique specific anti-DS antibodies LKN1 and GD3A12. Expression of the 4/2,4-di-
O-sulfated DS domain recognized by antibody LKN1 was decreased in the interstitium of
transplant kidneys with IF/TA, which was accompanied by an increased expression of type I
collagen, decorin and transforming growth factor beta (TGF-β), while its expression was
increased in the interstitium in FSGS, MGP and SLE. Importantly, all patients showed glomer-
ular LKN1 staining in contrast to the controls. Expression of the IdoA-Gal-NAc4SDS domain
recognized by GD3A12 was similar in controls and patients. Our data suggest a role for the
DS domain recognized by antibody LKN1 in renal diseases with early fibrosis. Further
research is required to delineate the exact role of different DS domains in renal fibrosis.
Introduction
Dermatan sulfate (DS) is a member of the large family of linear polysaccharides called glycos-
aminoglycans (GAGs). DS is also known as chondroitin sulfate B (CS-B) and is composed of
repeating disaccharide units consisting of N-acetyl galactosamine (GalNAc) and glucuronic
acid (GlcA) residues. The presence of the epimerized form of GlcA, iduronic acid (IdoA),
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defines it as DS. Covalently bound to a core protein DS forms proteoglycans (PGs), such as
decorin and biglycan [1, 2]. The level of complexity of DS is dictated by a variable structure
and chain length of up to 40–100 disaccharide units. The uronic acid can be either a GlcA or
IdoA with or without 2-O-sulfation, and the GalNAc residue can be 4- and/or 6-O-sulfated.
These possibilities can result in the formation of several defined disaccharide units; CSA (4-O-
sulfated), CSB/DS (IdoA and 2,4-di-O-sulfated), CSC (6-O-sulfated), CSD (2,6-di-O-sulfated),
CSE (4,6-di-O-sulfated) and CSEi (IdoA and 4,6-di-O-sulfated) [3].
DS is able to bind a myriad of factors, including fibroblast growth factor (FGF)-1, -2 &-7,
heparin cofactor II and interferon (IFN)-γ. Specific sulfation patterns and the amount of epi-
merization within a CS/DS chain dictate growth factor/cytokine binding and function, such as
cell proliferation, signal transduction and extracellular matrix (ECM) modulation [2]. The bio-
logical roles of both the proteoglycan core protein and the DS side chains have been studied,
mostly in relation to extracellular matrix components, especially collagens. These studies have
indicated fundamental roles of the DSPGs biglycan and decorin in regulating collagen fibril
formation in vivo [4, 5], while the DS side chains have been implicated in influencing the
mechanical strength of collagen fibrils in vitro as well [6]. The increase in extracellular matrix
and collagen is related to fibrosis and sclerosis.
Glomerulosclerosis and tubulointerstitial fibrosis are common final pathological features of
most end-stage kidney diseases irrespective of the underlying etiology [7]. It is also the final
common pathway of renal allograft damage, where the specific features are interstitial fibrosis
and tubular atrophy, which can lead to glomerulosclerosis resulting in a decline in glomerular
filtration rate [8]. Renal allograft injury can roughly be divided as acute, mediated by cellular
and/or antibody mediated rejection, or as chronic with moderate to severe interstitial fibrosis,
tubular atrophy and absence of specific glomerular pathology in an early stage (IF/TA) [9].
Tubulointerstitial fibrosis involves inflammation, proliferation, apoptosis and fibrosis. An early
identification of renal allograft loss could improve long-term allograft survival. Both acute and
chronic rejection are associated with increased chemokine expression, many of which are
GAG-binding [10]. There is an increase in circulating GAGs in patients with acute allograft
rejection [11] and experimental heparin/synthetic sulfated oligosaccharides therapy has been
shown to prolong transplant function and reduce rejection [12, 13]. It was shown that the
heparan sulfate (HS) PG expression was increased in sclerotic glomeruli, while the CSPG
expression was increased in the fibrotic interstitium in a renal transplant model in rats [10].
CS/DS and DSPGs have been reported to be increased in several fibrotic renal diseases, includ-
ing interstitial fibrosis, diabetic nephropathy, mesangial sclerosis and nephrosclerosis [14, 15].
Changes in CS/DS content and modifications have been found in different animal models for
renal disease [14, 16–18]. However, the precise role of DS in the ECM of both the normal and
the fibrotic kidney is not well understood. Importantly, little is known about structural alter-
ations in DS in renal diseases due to lack of proper tools for detection. In particular, specific
antibodies directed against specific domains in DS could further facilitate research on the role
of DS in renal fibrosis. Some antibodies recognizing both DS and CS have been described [19],
and previously we reported two specific anti-DS antibodies (GD3A12 and LKN1). The phage
displayed-derived anti-DS antibody LKN1 was shown to be especially reactive with 4/2,4-di-O-
sulfated DS, whereas antibody GD3A12 recognized IdoA-Gal-NAc4S [20, 21].
In the current study we elucidate the expression of the different DS domains defined by anti-
bodies LKN1 and GD3A12 using a panel of renal biopsies obtained from patients with acute
interstitial, acute vascular and chronic renal allograft rejections, and from patients with focal seg-
mental glomerulosclerosis (FSGS), membranous glomerulopathy (MGP) and systemic lupus ery-
thematosus (SLE). The expression of the DSPG decorin, type I collagen and transforming growth
factor beta (TGF-β) was investigated as well. Our data revealed that the 4/2,4-di-O-sulfated DS
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domain recognized by antibody LKN1 was differentially expressed in patients, while expression
of the IdoA-Gal-NAc4SDS domain recognized by GD3A12 was similar in controls and patients.
Materials and Methods
Human kidney specimens
This study was performed in accordance with the applicable rules concerning the review of
the research ethics committee of the Radboud university medical center Nijmegen. We used
archived renal biopsy material that was anonymized prior to us receiving these materials.
Renal allograft biopsies were obtained from patients with (according to Banff ‘97 guidelines
[22]) acute interstitial (n = 6; Banff’97 class I, C4d negative), acute humoral/vascular (n = 6;
Banff’97 class II, C4d positive) and chronic (n = 5; with slight to moderate fibrosis and tubular
atrophy, class II) rejection, later called “Interstitial fibrosis and tubular atrophy (IF/TA), with-
out evidence of any specific etiology” [23]. Note that these biopsies were previously obtained
and scored according to the Banff ‘97 guidelines. Needle renal biopsies were obtained from
patients with focal segmental glomerulosclerosis (FSGS, n = 11), membranous glomerulopathy
(MGP, n = 6), systemic lupus erythematosus (SLE, n = 6). Four renal biopsies not showing any
signs of rejection or other pathology were used as controls.
Immunofluorescence staining
Indirect immunofluorescence staining was performed on 2 μm cryostat renal sections. Sections
were fixed in ice-cold acetone for 10 minutes and incubated with primary antibodies diluted in
phosphate-buffered saline (PBS) containing 1% (w/v) bovine serum albumin (BSA, Sigma-Aldrich
Chemie BV, Zwijndrecht, The Netherlands) and 0.05% sodium azide (IF-buffer) for 45 minutes at
room temperature (RT). Primary antibodies included rabbit anti-bovine collagen type 1 (Millipore
BV, Amsterdam, The Netherlands), mouse anti-human decorin (R&D Systems Europe Ltd. Oxon,
United Kingdom), rabbit anti-transforming growth factor beta1 (TGF-β1) (Abcam, Cambridge,
United Kingdom) and the VSV-tagged anti-DS antibodies LKN1 [20] and GD3A12 [21]. Sections
were rinsed with PBS and incubated with anti-rabbit or anti-mouse Alexa 488-conjugated IgG
(5 μg/ml, Molecular Probes, Leiden, The Netherlands) or anti-VSV-Cy3 (2 μg/ml, Sigma-Aldrich
Chemie) in IF buffer for 45 minutes at RT. Sections were rinsed with PBS and subsequently fixed
in 100% ethanol for 20 seconds, air-dried and embedded in Mowiol. The staining intensities of all
antibodies were scored using arbitrary units (AU) on a scale between 0 and 4 (0 = no staining,
2 = intermediate staining and 4 = strong staining) by two investigators on blinded sections.
Statistical analysis
Data are presented as mean ± standard deviation (s.d.) and, if not normally distributed, as
median with interquartile ranges. For comparisons of different groups Mann-Whitney U tests
were used. Statistical analysis was performed using GraphPad Prism 5.0 (GraphPad Software
Inc., San Diego, CA, USA).
Results
Decreased expression of the 4/2,4-di-O-sulfated DS domain defined by
antibody LKN1 in the tubular interstitium in interstitial fibrosis and tubular
atrophy (IF/TA)
The distribution of the 4/2,4-di-O-sulfated and IdoA-Gal-NAc4S DS domains recognized by,
respectively, the LKN1 and GD3A12 antibody was analysed in biopsies with renal allograft
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rejection and controls (Figs 1 and 2). Relevant clinical data of the patients are given in Table 1.
In controls, the 4/2,4-di-O-sulfated DS domain defined by LKN1 was expressed in the tubular
interstitium, including the matrix surrounding Bowman’s capsule, with a distinct fibrillar
expression pattern (Fig 1A). No expression inside the glomerulus was seen. Previously, we
showed that this DS domain co-localized with type I collagen [20].
In IF/TA, expression of the 4/2,4-di-O-sulfated DS domain recognized by antibody LKN1
was significantly decreased in the tubular interstitium (Fig 1D), whereas the expression in the
acute interstitial (Fig 1B) and vascular renal allograft rejection (Fig 1C) was similar to the con-
trol kidneys (Figs 1A and 2A). The strongly decreased expression of the 4/2,4-di-O-sulfated DS
domain was accompanied by an increased expression of type I collagen, the DSPG decorin and
TGF-β in IF/TA (Figs 1L, 1P, 1T and 2A). Type I collagen and decorin expression in acute
interstitial (Fig 1J and 1N) and acute vascular renal allograft rejection (Fig 1K and 1O) was sim-
ilar to the control kidneys (Fig 1I and 1M). Furthermore, glomerular staining of LKN1 was
increased in IF/TA. and a similar increase also occurred in acute interstitial and vascular rejec-
tion (Fig 2B). Importantly, glomerular staining of TGF-β was also increased in acute interstitial
and vascular rejection, and in IF/TA (Figs 1R–1T and 2B) compared to the control kidneys
(Figs 1Q and 2B).
Fig 1. Expression of the 4/2,4-di-O-sulfated and IdoA-Gal-NAc4S DS domains defined by the antibodies LKN1 (A-D) and GD3A12 (E-H), type I
collagen (I-L), decorin (M-P) and TGF-β (Q-T) in renal allograft rejection and controls.Representative photographs showing the expression of the 4/
2,4-di-O-sulfated DS domain defined by LKN1 in the control human kidneys (A). Tubular interstitial expression of this 4/2,4-di-O-sulfated DS domain defined
by LKN1 was increased in acute interstitial (B) and acute vascular (C) renal allograft rejections compared to interstitial fibrosis and tubular atrophy (IF/TA) (D).
Expression of the IdoA-Gal-NAc4S DS domain recognized by GD3A12 was similar in the control human kidney and the three types of renal allograft rejection
(E-H), while expression of type I collagen (coll I) and decorin was increased in IF/TA (L, P) compared to the control human kidney (I, M), and acute interstitial
(J, N) and acute vascular renal allograft rejections (K, O). Glomerular expression of transforming growth factor beta (TGF-β) was increased in the three types
of renal allograft rejection (R-T) compared to the control human kidney (Q). Magnification A-P 100x, magnification Q-T 200x.
doi:10.1371/journal.pone.0134946.g001
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Fig 2. Semi-quantitative analysis of the expression of type I collagen, decorin, TGF-β and the 4/2,4-di-O-sulfated and IdoA-Gal-NAc4S DS domains
defined by LKN1 and GD3A12 in the interstitium (A) and glomeruli (B) in renal allograft rejection. Staining intensities of type I collagen, decorin,
transforming growth factor beta (TGF-β) and the DS domains defined by LKN1 and GD3A12 were scored using a scale of 0–4 and revealed a significantly
increased tubular interstitial expression of type I collagen, decorin and TGF-β and a decreased expression of the 4/2,4-di-O-sulfated DS domain recognized
by LKN1 in interstitial fibrosis and tubular atrophy (IF/TA). Expression of the IdoA-Gal-NAc4S DS domain recognized by GD3A12 was similar in controls and
the three types of renal allograft rejection (A). Glomerular expression of the 4/2,4-di-O-sulfated DS domain defined recognized by LKN1 and TGF-β was
increased in the acute interstitial, acute vascular and chronic renal allograft rejections compared to controls (B). *P<0.05 vs control.
doi:10.1371/journal.pone.0134946.g002
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The expression pattern of the IdoA-Gal-NAc4S DS domain recognized by the GD3A12
antibody in control kidney was similar to the expression pattern of the 4/2,4-di-O-sulfated DS
domain defined by LKN1. Thus, also in this case no glomerular expression was observed (Fig
1E). Furthermore, no differences were observed between the expression of this IdoA-Gal-
NAc4SDS domain in the control group (Fig 1E), and in the groups of patients with acute inter-
stitial (Fig 1F), acute vascular renal allograft rejection (Fig 1G) or IF/TA (Figs 1H and 2A).
Increased expression of the 4/2,4-di-O-sulfated DS domain defined by
antibody LKN1 in the tubular interstitium and glomeruli in human
glomerular diseases
Since these 2 specific DS domains were differentially expressed in the different types of renal
allograft rejection, we also analyzed their renal expression in three glomerular diseases FSGS,
MGP and SLE. Relevant clinical data of these patients are given in Table 2. In all these glomeru-
lar diseases, the 4/2,4-di-O-sulfated DS domain, recognized by the LKN1 antibody (Fig 3B–
3D), and type I collagen (Fig 3J–3L) were expressed in the glomerulus in contrast to the con-
trols (Figs 3A, 3I, and 4B). Furthermore, expression of this DS domain was significantly
increased in the tubular interstitium of patients with FSGS, MGP and SLE (Figs 3B–3D and
4A), which was accompanied by an increased expression of type I collagen as well (Figs 3J–3L
and 4A). Expression of TGF-β was increased in the tubular interstitium of patients with FSGS
and SLE (Figs 3R, 3T, and 4A). Importantly, the increased glomerular expression of the 4/
Table 1. Clinical characteristics of transplanted patients with rejection.
Patient Sex Age Original kidney disease Banff’97 Graft survival at
time of biopsy
SCreat (μmol/l)
at biopsy
Proteinuria (g/24h)
at biopsy
SCreat (μmol/l) at
last follow-up
1 F 27 Tubulo-interstitial nephritis I 10 months 170 0.4 Failure at 81
months
2 M 41 Infravesical obstruction I 8 days 247 3.7 150 at 72 months
3 F 39 Glomerulonephritis and
nephritic syndrome
Ia 16 months 107 0.25 99 at 108 months
4 M 39 ESRD unknown cause Ib 9 months 171 0.72 229 at 87 months
5 M 15 MPGN type I Ib 2 months 136 0.1 139 at 60 months
6 M 47 IgA nephropathy I 5 months 162 1.37 206 at 72 months
7 M 22 Hypoplasia Chronic 20 months 157 3.94 Failure at 23
months
8 M 40 ESRD unknown cause Chronic 16 months 154 3.82 229 at 87 months
9 M 21 Urethral valves Chronic 103 months 197 1.77 275 at 174
months
10 M 31 Urethral valves Chronic 202 months 900 N.A. Failure at 151
months
11 M 47 IgA nephropathy Chronic 5 months 162 0.83 199 at 44 months
12 M 27 IgA nephropathy IIa 9 months 149 0.43 143 at 84 months
13 M 66 Hemolytic uremic syndrome IIa 1 months 308 0.58 Failure at 1 month
14 M 31 Medullary cystic disease IIa 1 month 193 0.61 Failure at 25
months
15 M 53 ANCA-vasculitis IIa 9 months 152 0.43 337 at 81 months
16 F 43 Chronic pyelonephritis IIa 1 week 116 0.4 137 at 61 months
17 M 4 Urethral valves IIa 1 month 83 0 69 at 71 months
Abbreviations: SCreat, Serum creatinine; ESRD, End Stage Renal Disease; MPGN, Membranoproliferative glomerulonephritis; ANCA-vasculitis, Anti-
neutrophil cytoplasmic antibodies-associated vasculitis; N.A., not available.
doi:10.1371/journal.pone.0134946.t001
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2,4-di-O-sulfated DS domain was accompanied by an increased glomerular expression of
TGF-β (Figs 3R–3T and 4B) compared to the controls (Figs 3Q and 4B). In contrast to the
4/2,4-di-O-sulfated DS domain, the IdoA-Gal-NAc4S DS domain, recognized by the antibody
Fig 3. Expression of the 4/2,4-di-O-sulfated and IdoA-Gal-NAc4S DS domains defined by LKN1 (A-D) and GD3A12 (E-H), type I collagen (I-L),
decorin (M-P) and TGF-β (Q-T) in renal sections obtained from patients with glomerular diseases.Representative photographs showing the
immunofluorescence stainings of renal sections obtained from controls (A, E, I, M, Q), patients with focal segmental glomerulosclerosis (FSGS) (B, F, J, N,
R), membranous glomerulopathy (MGP) (C, G, K, O, S) and systemic lupus erythematosus (SLE) (D, H, L, P, T) with the anti-DS antibodies LKN1 (A-D) and
GD3A12 (E-H), anti-collagen type I (Coll I) (I-L), decorin (M-P) and transforming growth factor beta (TGF-β) (Q-T). Tubular interstitial and glomerular
expression of the 4/2,4-di-O-sulfated DS domain defined by LKN1 and of type I collagen was increased in FSGS (B, J), MGP (C, K) and SLE (D, L) compared
to control human kidney (A, I). Expression of the IdoA-Gal-NAc4S DS domain, recognized by GD3A12, and decorin was similar in the interstitium and
glomeruli of patients (F-H, N-P) and controls (E, M). Glomerular expression of TGF-βwas increased in FSGS (R), MGP (S) and SLE (T) compared to control
(Q). Magnification A-P 100x, magnification Q-T 200x.
doi:10.1371/journal.pone.0134946.g003
Table 2. Characteristics of patients with glomerular diseases.
FSGS MGP SLE*
N 11 6 6
Male (N) 9 4 0
Age (years) 54.3 (20–68) 55.2 (33–70) 25.8 (19–74)
Endogenous creatinine clearance (ml/min) 107 (24–163) 104 (30–153) 92 (36–136)
Serum albumin (g/l) 25 (14–42) 21 (12–24) 31 (24–45)
Proteinuria (g/day) 9.1 (5–15) 8.1 (2.5–15) 2.9 (0.8–15)
Glomerulosclerosis (0–3) 1 (0–3) 1 (0–1) 0 (0–2)
Interstitial ﬁbrosis and tubular atrophy (0–3) 1 (0–3) 0.5 (0–3) 1 (1–2)
Values are given as median and range. Abbreviations: FSGS, focal segmental glomerulosclerosis; MGP, membranous glomerulopathy; SLE, systemic
lupus erythematosus. Glomerulosclerosis, interstitial ﬁbrosis and tubular atrophy were scored as absent (0), < 25% (1), 25–50% (2), > 50% (3).
*All SLE patients had proliferative lupus nephritis (ISN/RPS class III: N = 3; class IV: N = 3).
doi:10.1371/journal.pone.0134946.t002
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Fig 4. Semi-quantitative analysis of the expression the 4/2,4-di-O-sulfated and IdoA-Gal-NAc4S DS domains defined by LKN1 and GD3A12, type I
collagen, decorin and TGF-β in the interstitium (A) and glomeruli (B) of patients with FSGS, MGP and SLE. Staining intensities of the 4/2,4-di-O-
sulfated and IdoA-Gal-NAc4S DS domains defined by LKN1 and GD3A12 respectively and of type I collagen, decorin and transforming growth factor beta
(TGF-β) were scored using a scale of 0–4 and revealed a significantly increased expression of the 4/2,4-di-O-sulfated DS domain and type I collagen in the
interstitium (A) and glomeruli (B) of patients with glomerular diseases. Glomerular expression of TGF-β also was increased in patients with glomerular
diseases (B), while expression of the IdoA-Gal-NAc4S DS domain and decorin was similar in the interstitium (A) of patients and controls. *P<0.05 vs control.
doi:10.1371/journal.pone.0134946.g004
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GD3A12, and decorin were not expressed in the glomeruli of patients with glomerular diseases
(Fig 3F–3H and 3N–3P). Furthermore, the expression of the IdoA-Gal-NAc4S DS domain and
decorin in the tubular compartment was similar in both normal and glomerular diseased kid-
neys (Figs 3E–3H, 3M–3P and 4A).
In summary, we observed a differential expression of the 4/2,4-di-O-sulfated DS domain,
recognized by antibody LKN1, in renal transplant rejection and glomerular pathologies. We
analyzed the correlation between the expression of 4/2,4-di-O-sulfated DS domain recognized
by antibody LKN1 and type I collagen in glomerular diseases, acute rejection and IF/TA, which
may clarify the difference of LKN1 staining in the different renal diseases (Fig 5A). We
observed 3 patterns; 1) in acute allograft rejection expression of the 4/2,4-di-O-sulfated DS
domain recognized by LKN1 is increased more than collagen type I; 2) in glomerular disease
both expressions are increased; 3) but in IF/TA expression of the 4/2,4-di-O-sulfated DS
domain is decreased, while collagen type I is increased. In contrast to the differential interstitial
expression of the 4/2,4-di-O-sulfated DS domain recognized by antibody LKN1 among the var-
ious renal diseases, the expression of the IdoA-Gal-NAc4S DS domain recognized by GD3A12
is similar in healthy and diseased kidneys. Therefore, the expression ratio of 4/2,4-di-O-sul-
fated DS domain to IdoA-Gal-NAc4S DS domain might be useful in monitoring the progres-
sion of IF/TA (Fig 5B). This information may be useful for diagnostic purposes on renal
biopsies.
Discussion
This study shows the differential expression of the specific 4/2,4-di-O-sulfated and IdoA-Gal-
NAc4S DS domains recognized by the anti-DS antibodies LKN1 and GD3A12, respectively, in
normal kidney and in renal pathology. Previous studies showed the expression of DS (and CS)
in the kidney, both in the glomerulus and in the tubular interstitium [14, 24, 25]. The 4/2,4-di-
O-sulfated DS domain is expressed in the tubular interstitial space, but not in the healthy glo-
merulus, as is type I collagen [20]. Furthermore, the normal expression pattern of the 4/2,4-di-
O-sulfated DS domain resembles the expression of the two DSPGs, decorin and biglycan,
which are also expressed in the renal tubular interstitium with accumulations around the
tubules, but no expression in the normal glomerulus [15, 26]. For the IdoA-Gal-NAc4S DS
domain, the expression pattern in control rat kidney was previously shown in large blood ves-
sels with a weaker staining present in the tubular interstitial space and near Bowman’s capsule
[21]. DS and DSPGs have been reported to be increased in several fibrotic renal diseases,
including interstitial fibrosis, diabetic nephropathy, mesangial sclerosis and nephrosclerosis
[14, 15]. In the unilateral urethral obstruction (UUO) model in the rat, a well established
model of renal inflammation and fibrosis, fibrotic lesions showed ten-fold increase in CS/DS
content and a decrease in the sulfation degree of CS/DS, accompanied by a lower IdoA content
[14].
The expression of the 4/2,4-di-O-sulfated DS domain recognized by LKN1 was significantly
decreased in the tubular interstitium in biopsies of patients with IF/TA compared to biopsies of
patients with acute rejection. In IF/TA there was an inverse correlation between the decreased
expression of the 4/2,4-di-O-sulfated DS domain and the increased expression of decorin,
TGF-β and type I collagen. Importantly, glomerular LKN1 staining was not observed in con-
trols, while patients with different forms of renal allograft rejections did show a glomerular
LKN1 staining. The increased glomerular expression of the 4/2,4-di-O-sulfated DS domain
correlated with the increased glomerular expression of TGF-β in the biopsies with acute rejec-
tion and IF/TA, which corresponds to other studies [27, 28]. In biopsies of patients with glo-
merular disease, there was also an increased glomerular expression of the 4/2,4-di-O-sulfated
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Fig 5. Correlation between the expression of the 4/2,4-di-O-sulfated DS domain recognized by antibody LKN1 and type I collagen (A) and the
expression ratio of LKN1 and GD3A12 (B) in glomerular diseases, acute rejection and IF/TA. In acute (vascular and interstitial) rejection, the interstitial
expression of the 4/2,4-di-O-sulfated DS domain recognized by antibody LKN1 is increased, while expression of collagen type I is decreased (A). Expression
of collagen type I is increased in glomerular diseases and IF/TA, which is accompanied by an increased expression of the 4/2,4-di-O-sulfated DS domain in
glomerular diseases and a decreased expression of the 4/2,4-di-O-sulfated DS domain in IF/TA. The expression ratio of the 4/2,4-di-O-sulfated DS domain
recognized by antibody LKN1 to the IdoA-Gal-NAc4S DS domain recognized by antibody GD3A12 is decreased in the IF/TA patients in contrast to the
patients with acute rejection or glomerular diseases (B).
doi:10.1371/journal.pone.0134946.g005
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DS domain, which was accompanied by glomerular expression of type I collagen and TGF-β.
These data are in accordance to other studies that showed an upregulated expression of small
leucine-rich proteoglycans and type I collagen in renal fibrosis, diabetic nephropathy and cres-
centic glomerulonephritis [29–31]. The expression of the 4/2,4-di-O-sulfated DS domain was
significantly increased in the tubular interstitium of patients with glomerular disease, which
was again accompanied by an increased expression of type I collagen, suggesting a role for this
4/2,4-di-O-sulfated DS domain in matrix remodelling and collagen formation in glomerular
disease. In patients with FSGS and SLE, the increased expression of the 4/2,4-di-O-sulfated DS
domain in the tubular interstitium, correlated with the increased expression of TGF-β, which
was in accordance with the degree of interstitial fibrosis and tubular atrophy. This was also
shown by other studies [32, 33]. Since the specific 4/2,4-di-O-sulfated DS domain is present at
an earlier stage in the analyzed nephropathies, this anti-DS antibody might be useful in deter-
mining early changes in matrix deposition in the diseased kidney. It has been described that DS
size increases in response to an insult, but returns to normal later on, thus regulating collagen
fibril formation [34]. The increase in DS staining observed in the tubular interstitium using our
anti-DS antibody LKN1 might reflect the changes in DS size and sulfation needed for initial
matrix modelling. Type I collagen depositions were present in the analyzed glomerular diseases
and there was a positive correlation with the expression of the DSPG decorin, TGF-β and the
specific 4/2,4-di-O-sulfated DS domain recognized by LKN1, which indicates that the specific
4/2,4-di-O-sulfated DS domain plays different pathophysiological roles in renal allograft rejec-
tion and glomerular diseases. In IF/TA intima fibrosis/hyperplasia leads to arteriolopathy,
which can induce ischemia. It is tempting to speculate that ischemia may induce a decreased
expression of the specific 4/2,4-di-O-sulfated DS domain in contrast to the increased expres-
sion in glomerular diseases with less or no ischemia. Another study [35] showed that increased
6-O-sulfation of HS regulates the fibrotic response associated with chronic renal allograft fail-
ure. Interestingly, TGF-β induced up regulation of HS-6-O-endosulfatase-2 expression, which
led to this changed sulfation pattern. In our study, the expression of the sulfotransferases der-
matan 4-O-sulfotransferase 1 and /or the CS/DS-2-O-sulfotransferase may be changed in the
glomeruli and tubular interstitium during the different stages of renal allograft rejection and
glomerular diseases, causing differential expression of specific sulfated DS domains.
In contrast to the differential expression of the 4/2,4-di-O-sulfated DS domain in the con-
trol, the different types of renal allograft rejections and the glomerular diseases, the expression
of the IdoA-Gal-NAc4S DS domain recognized by the anti-DS antibody GD3A12 was not dif-
ferent for either the tubular interstitium or the glomerulus. Therefore, these data indicate a
dynamic role for the specific DS domains defined by the anti-DS antibody LKN1 in renal dis-
eases. Moreover, it has been shown that GAGs are involved in chemokine sequestration in
renal allograft rejection, allowing an inflammatory reaction to take place which can ultimately
lead to transplant rejection [36]. An increase in CS expression was seen during acute renal allo-
graft rejection and the biopsy specimens showed an enhanced capacity of binding a specific
chemokine (CCL5). In a recent study using an experimental renal transplantation model an up
regulation of the CSPG versican in kidneys with increased interstitial fibrosis was shown [10].
In summary, we observed a differential expression of DS domains when comparing healthy
kidneys and diseased kidneys. Our data suggest a role for the 4/2,4-di-O-sulfated DS domain
recognized by antibody LKN1 in renal diseases with early fibrosis. However, further research is
required to delineate the exact role of different DS domains in renal fibrosis. The described
anti-DS antibodies might contribute to the future development of glycomimetics, which may
ultimately lead to a better treatment of selected renal nephropathies and prevention of renal
rejection.
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